[go: up one dir, main page]

ES2001019A6 - Procedimiento para preparar hidroxialquilxantinas terciarias - Google Patents

Procedimiento para preparar hidroxialquilxantinas terciarias

Info

Publication number
ES2001019A6
ES2001019A6 ES8600356A ES8600356A ES2001019A6 ES 2001019 A6 ES2001019 A6 ES 2001019A6 ES 8600356 A ES8600356 A ES 8600356A ES 8600356 A ES8600356 A ES 8600356A ES 2001019 A6 ES2001019 A6 ES 2001019A6
Authority
ES
Spain
Prior art keywords
formula
compounds
carbon
manufacturing process
tertiary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8600356A
Other languages
English (en)
Inventor
Ulrich Gebert
Ismahan Okyayuz-Baklouti
Werner Thorwart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of ES2001019A6 publication Critical patent/ES2001019A6/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

EL PROCEDIMIENTO DESCRITO PREPARA COMPUESTOS DE FORMULA I DONDE AL MENOS UNO DE LOS RADICALES R1 Y R3 REPRESENTA UN GRUPO HIDROXIALQUILO TERCIARIO Y EL OTRO DE ESOS RADICALES, EVENTUALMENTE EXISTENTE, REPRESENTA HIDROGENO O UN RADICAL HIDROCARBONADO ALIFATICO, Y R2 REPRESENTA UN GRUPO ALQUILO DE 1 A 4 ATOMOS DE CARBONO, HACIENDO REACCIONAR 3-ALQUILXANTINAS DE FORMULA DONDE R2 ES COMO SE HA DEFINIDO ANTES, CON AGENTES ALQUILANTES DE FORMULA DONDE X ES HALOGENO O UNA AGRUPACION ESTER DE ACIDO SULFONICO O DE ACIDO FOSFORICO, R4 ES ALQUILO DE HASTA 3 ATOMOS DE CARBONO Y N ES 2 A 5. LOS COMPUESTOS DE FORMULA I SE PUEDEN PREPARAR TAMBIEN SIGUIENDO VIAS ALTERNATIVAS EXPLICADAS EN LA MEMORIA. ESTOS COMPUESTOS SON ESPECIALMENTE ADECUADOS PARA TRATAR ALTERACIONES DE LA CIRCULACION SANGUINEA PERIFERICA Y CEREBRAL.
ES8600356A 1985-07-19 1986-07-17 Procedimiento para preparar hidroxialquilxantinas terciarias Expired ES2001019A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853525801 DE3525801A1 (de) 1985-07-19 1985-07-19 Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung

Publications (1)

Publication Number Publication Date
ES2001019A6 true ES2001019A6 (es) 1988-04-16

Family

ID=6276182

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8600356A Expired ES2001019A6 (es) 1985-07-19 1986-07-17 Procedimiento para preparar hidroxialquilxantinas terciarias

Country Status (33)

Country Link
US (1) US4833146A (es)
EP (1) EP0268585B1 (es)
JP (1) JPH0788382B2 (es)
KR (1) KR950001019B1 (es)
CN (1) CN1026112C (es)
AR (1) AR244689A1 (es)
AT (1) ATE53211T1 (es)
AU (1) AU588350B2 (es)
BG (1) BG60767B2 (es)
CA (1) CA1262248A (es)
CS (1) CS272766B2 (es)
DD (1) DD261156A5 (es)
DE (2) DE3525801A1 (es)
DK (1) DK157867C (es)
ES (1) ES2001019A6 (es)
FI (1) FI89921C (es)
GR (1) GR861866B (es)
HU (1) HU198486B (es)
IE (1) IE59025B1 (es)
IL (1) IL79457A0 (es)
LT (1) LT3869B (es)
LV (1) LV5703A3 (es)
MA (1) MA20739A1 (es)
MX (1) MX9254A (es)
NO (1) NO165803C (es)
NZ (1) NZ216888A (es)
OA (1) OA08707A (es)
PH (1) PH26262A (es)
PT (1) PT83013B (es)
RU (1) RU2051918C1 (es)
TN (1) TNSN86111A1 (es)
WO (1) WO1987000523A2 (es)
ZA (1) ZA865374B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8621870D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Active compounds
US5338741A (en) * 1986-10-27 1994-08-16 Nestec S.A. 1-hydroxyalkylxanthines and medicaments containing them
JP2661666B2 (ja) * 1988-02-19 1997-10-08 ヘキスト薬品工業株式会社 抗消化性潰瘍剤
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
DD298051A5 (de) * 1989-08-16 1992-02-06 ��@���������@�������k�� Verfahren zur herstellung eines therapeutischen agens zur behandlung von verdauungskrankheiten
GB8924392D0 (en) * 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
EP0430300A3 (en) * 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
DE3942872A1 (de) * 1989-12-23 1991-06-27 Hoechst Ag Verfahren zur enantioselektiven darstellung von ((omega)-1)-hydroxyalkylxanthinen
IT1240843B (it) * 1990-05-24 1993-12-17 Malesci Istituto Farmacobiologico Derivati xantinici 1-7 sostituiti ad attivita' antiasmatica, loro sali fisiologicamente accettabili, loro composizioni farmaceutiche e procedimento per la loro preparazione.
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5039666A (en) * 1990-10-30 1991-08-13 Hoechst-Roussel Pharmaceuticals Inc. Aminoglycoside composition having substantially reduced nephrotoxicity induced by the aminoglycoside
ES2087205T3 (es) * 1990-11-07 1996-07-16 Hoechst Roussel Pharma Uso de xantinas para la preparacion de un medicamento eficaz para inhibir la replicacion de retrovirus humanos.
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
MX9203323A (es) * 1991-07-11 1994-07-29 Hoechst Ag El empleo de derivados de xantina para el tratamiento de lesiones secundarias de las celulas nerviosas y trastornos funcionales despues de traumas craneo-cerebrales.
TW209834B (es) * 1991-12-11 1993-07-21 Hoechst Ag
DE59304710D1 (de) * 1992-02-22 1997-01-23 Hoechst Ag Verwendung von Xanthinderivaten zur Behandlung von Muskelschädigungen nach vollständiger Unterbrechung der Blutzirkulation
CA2112239C (en) * 1992-03-04 2000-05-09 James A. Bianco Enantiomeric hydroxylated xanthine compounds
EP0570831A2 (de) * 1992-05-20 1993-11-24 Hoechst Aktiengesellschaft Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
US5817662A (en) * 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5804584A (en) * 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
US5473070A (en) * 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5866576A (en) * 1992-12-16 1999-02-02 Cell Therapeutics, Inc. Epoxide-containing compounds
WO1994015605A1 (en) * 1993-01-14 1994-07-21 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
AU6092794A (en) * 1993-01-19 1994-08-15 Cell Therapeutics, Inc. Oxime-substituted therapeutic compounds
US5641783A (en) * 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
US5837703A (en) * 1993-03-31 1998-11-17 Cell Therapeutics, Inc. Amino-alcohol substituted cyclic compounds
US6020337A (en) * 1993-04-05 2000-02-01 Cell Therapeutics, Inc. Electronegative-substituted long chain xanthine compounds
CA2192470A1 (en) * 1994-01-14 1995-07-20 Paul A. Brown Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
EP0746557A4 (en) * 1994-02-18 1997-05-02 Cell Therapeutics Inc INTRACELLULAR SIGNALING MEDIATORS
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US5801182A (en) * 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
DE19540798A1 (de) * 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel
US5965555A (en) * 1996-06-07 1999-10-12 Hoechst Aktiengesellschaft Xanthine compounds having terminally animated alkynol side chains
DE59708533D1 (de) * 1996-06-07 2002-11-28 Hoechst Ag Verwendung von Theophyllinderivaten zur Behandlung und Propylaxe von Schockzuständen, neue Xanthinverbindungen und Verfahren zu deren Herstellung
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
US5981536A (en) * 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US5985592A (en) * 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
US6075029A (en) * 1998-01-02 2000-06-13 Cell Therapeutics, Inc. Xanthine modulators of metabolism of cellular P-450
US20030207901A1 (en) * 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
RU2157209C1 (ru) * 2000-03-23 2000-10-10 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Улучшающее мозговое кровообращение, антиагрегатное средство и способ его получения
DE10042152A1 (de) * 2000-08-26 2002-03-28 Basf Coatings Ag Mit aktinischer Strahlung aktivierbares Thixotropierungsmittel, Verfahren zu seiner Herstellung und seine Verwendung
DE10122390A1 (de) * 2001-05-09 2002-11-28 Basf Coatings Ag Carbamat-und/oder Allophanatgruppen enthaltende, thermisch härtbare, thixotrope Gemische
DE10139262C1 (de) * 2001-08-09 2003-01-02 Basf Coatings Ag Rheologiehilfsmittel, Verfahren zu seiner Herstellung und seine Verwendung
US20050119422A1 (en) * 2002-04-24 2005-06-02 Basf Corporation Thermally curable, thixotropic mixtures containing carbamate and/or allophanate groups
KR100872788B1 (ko) * 2002-05-28 2008-12-09 엘지전자 주식회사 드럼세탁기
US8686090B2 (en) * 2003-12-10 2014-04-01 Basf Coatings Gmbh Use of urea crystals for non-polymeric coatings
US20080081816A1 (en) * 2006-10-03 2008-04-03 Kaohsiung Medical University Anti-inflammation activity of newly synthesized xanthine derivatives kmup-1 and kmup-3
EP2265334A2 (en) * 2008-02-29 2010-12-29 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US8546572B2 (en) * 2008-03-31 2013-10-01 Sun Pharmaceutical Industries Limited Process for the preparation of morphinane analogues
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
WO2011028820A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
EP2473052A4 (en) 2009-09-02 2013-03-20 Concert Pharmaceuticals Inc SUBSTITUTED XANTHINE DERIVATIVES
US9085788B2 (en) 2010-09-01 2015-07-21 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
WO2012031073A1 (en) 2010-09-01 2012-03-08 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
CN104364255A (zh) 2012-04-13 2015-02-18 康塞特医药品有限公司 取代的黄嘌呤衍生物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1245969B (de) * 1967-08-03 VEB Arzneimittelwerk Dresden, Radebeul Verfahren zur Herstellung von Xanthinderivaten
US2517410A (en) * 1947-08-15 1950-08-01 Searle & Co Hydroxy alkyl xanthines and the production thereof
FR1211333A (fr) * 1955-10-19 1960-03-15 Boehringer Sohn Ingelheim Perfectionnements apportés aux procédés pour fabriquer des oxyalcoylxanthines
US4576947A (en) * 1967-12-16 1986-03-18 Hoechst Aktiengesellschaft Pharmaceutical compositions
DE2335170C2 (de) * 1973-07-11 1989-07-20 Hoechst Ag, 6230 Frankfurt 1,3-Dialkyl-7-(hydroxyalkyl)-xanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
BE795345A (fr) * 1972-02-19 1973-08-13 Albert Ag Chem Werke MEDICAMENT UTILE NOTAMMENT POUR L'IRRIGATION CEREBRALE, PROCEDE DE PREPARATION DE SES MATIERES ACTIVES ET CES MATIERES ElLES-MEMES
CH622519A5 (en) * 1974-07-05 1981-04-15 Hoechst Ag Process for the preparation of hydroxyalkylxanthines
DE2432702C2 (de) * 1974-07-08 1983-01-20 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von Hydroxyalkylxanthinen
CA1075690A (en) * 1974-12-13 1980-04-15 Hoechst Aktiengesellschaft Xanthine derivatives
DE3062499D1 (en) * 1979-04-05 1983-05-05 Beecham Wuelfing Gmbh & Co Kg Dialkoxy- and dioxacycloalkyl-alkyltheobromines, pharmaceutical compositions containing them and their preparation
JPS5838284A (ja) * 1981-09-01 1983-03-05 Teikoku Chem Ind Corp Ltd １−（５′−オキソヘキシル）−３，７−ジメチルキサンチンの製造方法
DE3138397A1 (de) * 1981-09-26 1983-04-07 Hoechst Ag, 6230 Frankfurt "arzneimittel, darin enthaltene vicinale dihydroxyalkylxanthine und herstellungsverfahren fuer diese xanthinverbindungen"
US4575795A (en) * 1983-04-01 1986-03-11 Honeywell Information Systems Inc. Apparatus for detecting a predetermined character of a data string

Also Published As

Publication number Publication date
JPH0788382B2 (ja) 1995-09-27
ATE53211T1 (de) 1990-06-15
LT3869B (en) 1996-04-25
JPS63501149A (ja) 1988-04-28
NO871111D0 (no) 1987-03-18
DD261156A5 (de) 1988-10-19
BG60767B2 (bg) 1996-02-29
PH26262A (en) 1992-04-01
FI880174A0 (fi) 1988-01-15
DK139287A (da) 1987-03-18
EP0268585A1 (de) 1988-06-01
CA1262248A (en) 1989-10-10
IL79457A0 (en) 1986-10-31
AU6143986A (en) 1987-02-10
FI89921C (fi) 1993-12-10
CS272766B2 (en) 1991-02-12
MA20739A1 (fr) 1987-04-01
US4833146A (en) 1989-05-23
HU198486B (en) 1989-10-30
CN1026112C (zh) 1994-10-05
KR870700623A (ko) 1987-12-30
FI880174L (fi) 1988-01-15
NO165803B (no) 1991-01-02
IE59025B1 (en) 1993-12-15
LV5703A3 (lv) 1995-02-20
KR950001019B1 (ko) 1995-02-07
ZA865374B (en) 1987-02-25
NO871111L (no) 1987-03-18
PT83013B (pt) 1989-01-30
EP0268585B1 (de) 1990-05-30
AR244689A1 (es) 1993-11-30
DK157867C (da) 1990-07-30
AU588350B2 (en) 1989-09-14
DK139287D0 (da) 1987-03-18
FI89921B (fi) 1993-08-31
LTIP1467A (en) 1995-05-25
NO165803C (no) 1991-04-10
OA08707A (en) 1989-03-31
PT83013A (de) 1986-08-01
CS545386A2 (en) 1990-04-11
DE3525801A1 (de) 1987-01-22
WO1987000523A3 (en) 1987-02-26
RU2051918C1 (ru) 1996-01-10
GR861866B (en) 1986-11-17
CN86105835A (zh) 1987-01-14
IE861917L (en) 1987-01-19
NZ216888A (en) 1989-05-29
DE3671627D1 (de) 1990-07-05
MX9254A (es) 1993-06-01
DK157867B (da) 1990-02-26
HUT47274A (en) 1989-02-28
TNSN86111A1 (fr) 1990-01-01
WO1987000523A2 (en) 1987-01-29

Similar Documents

Publication Publication Date Title
ES2001019A6 (es) Procedimiento para preparar hidroxialquilxantinas terciarias
AR241222A1 (es) Procedimiento para elaborar nuevos acidos 3-amino- (1) benzazepin-2-alcanoicos y sus sales.
AR245707A1 (es) Procedimiento para preparar 11-(4-¡2-(2-hidroxietoxi)etil¿-piperazinil)-dibenzo¡b,f¿¡1,4¿tiazepina
ES2040261T3 (es) Procedimiento para preparar acidos 6-fluor-4-oxo-1,4-dihidroquinolina-3-carboxilicos sustituidos y acidos 9-fluor-3-metil-7-oxo-2,3-dihidro-7h-pirido(1,2,3-de)(1,4)benzoxazina-6-carboxilico sustituidos.
KR860004850A (ko) 1α-히드록시 비타민 D₃유도체의 제조방법
ES523943A0 (es) Procedimiento para la fabricacion de nuevos derivados de la tieno (3,2-c) piridina
ATE96664T1 (de) Nicht-beta-oxidierbare fettsaeure-analoge, die die blutkonzentration von cholesterin und triglyceriden bei saeugetieren senken.
ATA438383A (de) Verfahren zum herstellen von neuen carboxamidoderivaten von 5h-1,3,4-thiadiazolo(3,2-a)-pyrimidinen und ihren pharmazeutisch unbedenklichen salzen
DE3587777D1 (de) Heterozyklische Verbindungen, deren Herstellung und Medikamente diese enthaltend.
ES2059557T3 (es) Nuevas bis-(3,5-dicarbamoil-2,4,6-triyodo-anilidas) de acidos dicarboxilicos, procedimiento para su preparacion asi como agentes de contraste de rayos x que contienen a estos.
FI842760A0 (fi) Menetelmä terapeuttisesti aktiivisten imidatsoliumyhdisteiden valmistamiseksi
HUT35659A (en) Process for producing 4-amino-methylene-chromane- and-chromene-derivatives and pharmaceutical compositions containing them as active agents
ES2087854T3 (es) Nuevos oxatiolanos y derivados de los mismos, composiciones farmaceuticas que los contienen y el uso de los mismos como medicamentos.
SE8304006D0 (sv) Forening och komposition for terapeutisk eller diagnostisk anvendning samt forfarande for terapeutisk behandling
ATE50571T1 (de) Dihydropyridin-carbonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln.
AR241422A1 (es) Procedimiento para la preparacion de derivados de difenil(metil-etil-0 etenil) piperidinas.
ES2096413T3 (es) Derivado de acido 5-amino-8-metil-7-pirrolidinilquinoleina-3-carboxilico.
ES2064328T3 (es) Indolilpropanoles, procedimiento para su fabricacion y su uso, asi como preparaciones que contienen los compuestos.
PT82848B (pt) Processo para a preparacao de novas 5,11-dihidro-6h-pirido{2,3-b} {1,4}-benzodiazepina-6-onas substituidas na posicao 11 e de composicoes farmaceuticas que as contem
ES8405391A1 (es) Un procedimiento para la preparacion de un derivado de tetrahidro-1h-piridoindol.
ES2040294T3 (es) Nuevos compuestos de azufre, procedimientos para su preparacion, asi como medicamentos.
ES2058203T3 (es) Derivados del acido pirocatequincarboxilico, su obtencion y empleo como substancias activas para medicamentos.
ES2063771T3 (es) Nuevos derivados de amida del acido 4-oxo-4h-pirido (1,2-a) pirimidin-3-carboxilicos, su preparacion y elaboracion de medicamentos que contienen estos compuestos, asi como la preparacion de los mismos.
ES2081834T3 (es) Pirrolidin-2-onas 4-metil y 4-etil sustituidas.
DE3782207D1 (de) 2-acyloxypropylamin-derivate, verfahren zur herstellung und diese enthaltende arzneimittel.